Bayer's Strategic Pivot Hinges on Pipeline and Patents

Bayer targets 30% pharma margin by 2030, driven by new drugs Nubeqa and Kerendia, but faces patent expirations for Xarelto and Eylea and ongoing Roundup litigation.

Investors in Bayer are navigating a complex transition. The German conglomerate is banking on a new generation of pharmaceuticals to power growth, even as it contends with significant patent expirations and a persistent legal overhang. The company's strategic ambitions, including a target to achieve a 30 percent operating margin in its pharmaceuticals division by 2030, face a critical test in the coming years.

The virtual Annual General Meeting on Friday, April 24, offers shareholders a chance to question management directly. On the agenda are a proposed dividend of EUR 0.11 per share—unchanged from the prior year—and a vote on two new supervisory board members. The ex-dividend date is set for April 27.

Financially, the company has made progress on debt reduction. Net financial debt declined to approximately EUR 29.8 billion by the end of 2025, a drop of over eight percent, supported by strong operational cash flows. Management reaffirmed its full-year targets at a recent Pharma Media Day, forecasting 2026 sales between EUR 45 and 47 billion and EBITDA before special items of EUR 9.6 to 10.1 billion.

The core of Bayer's growth narrative rests on two recently launched drugs. Its prostate cancer treatment Nubeqa generated EUR 2.4 billion in revenue last year, a 57 percent increase. The kidney disease drug Kerendia also posted robust growth, with annual sales reaching EUR 829 million and the company targeting a long-term goal of EUR 3 billion in annual revenue. A third approval for Nubeqa in China, expected this year, could provide a further boost.

However, this promising growth is set against the looming loss of exclusivity for legacy blockbusters. The patents for blood thinner Xarelto and eye treatment Eylea are expiring, creating a significant headwind. Company executives have labeled 2026 as the final year of consolidation for the pharma unit, with a return to mid-single-digit growth anticipated from 2027 onward.

A potential wildcard in the pipeline is the anticoagulant Asundexian. Phase III trial data published in the New England Journal of Medicine showed the drug reduced stroke risk by 26 percent without increasing bleeding risk—a breakthrough result for its class of Factor XIa inhibitors. This positions Asundexian as a critical medium-term growth driver.

External challenges persist. While management, including Pharma COO Sebastian Guth, has downplayed the impact of potential new U.S. import tariffs on pharmaceuticals—citing existing trade agreements that typically cap such duties at 15 percent—the ongoing Roundup litigation remains a major uncertainty. The pending Supreme Court case continues to cast a shadow over the stock's valuation.

Analyst sentiment has recently improved. DZ Bank upgraded the stock to "Hold" with a price target of EUR 44, while Deutsche Bank significantly raised its target from EUR 23 to EUR 43. The share price, consolidating around EUR 40.69 after a near 94 percent gain year-to-date, now faces a pivotal period. Positive signals from the shareholder meeting and regulatory progress in China could be the catalysts needed for a decisive move higher.